Clinical trials: Chronic Hepatitis Delta
Chronic Hepatitis B, Acute Hepatitis B
Disease Loads and Status of Treatment
The aim of study is to evaluate the current prevalence of HDV infection, and comprehensively analyze the interaction between HDV and HBV infections in the era of NAs in Taiwan.
- Conditions
- Chronic Hepatitis B, Acute Hepatitis B, Hepatitis D
- Trial name
- NCT05264272
- Testing
- Prospective serological assays, Retrospective serological assays
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Hepatitis B, Hepatitis D
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Patients with chronic HBV infection will receive either ARC-520 alone or ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated interferon (PEG IFN) alpha 2a therapy, and be…
- Trial name
- MONARCH (NCT02577029)
- Testing
- ARC-520, entecavir, pegylated interferon alpha 2a
- Where
- 33 sites in Australia, Bulgaria and 6 more
- Volunteers
- 79 people
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis D
HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis
Randomized, double blind study comparing the efficacy of pegylated interferon-alfa2a plus placebo versus pegylated interferon-alfa2a plus tenofovir for the treatment of chronic delta hepatitis.
- Trial name
- HIDIT-II (NCT00932971)
- Testing
- PEG-IFN alfa-2a, Tenofovir
- Where
- 10 sites in Germany, Greece and 1 more
- Volunteers
- 70 people
- Sponsor
- HepNet Study House, German Liverfoundation
Chronic Delta Hepatitis
Titrating-Dose of Lonafarnib in Combination With Ritonavir
A phase 2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of titrating-dose lonafarnib/ritonavir in patients chronically infected with hepatitis delta virus (HDV)
- Trial name
- LOWR-4 (NCT02527707)
- Testing
- lonafarnib, Ritonavir
- Volunteers
- 15 people
- Sponsor
- EIT Pharma, Inc.
Chronic Hepatitis Delta
Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
Background: Chronic hepatitis D is a serious liver disease caused by a virus. Currently, no medications are approved to treat chronic hepatitis D. Objective: To test a combination of 3 drugs in people with chronic hepatitis D.
- Trial name
- NCT05953545
- Testing
- Peginterferon Lambda
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis D
Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment
Pharmacological, single-center, non-profit observational study. The present study is part of a cooperation project between the SC Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Milan…
- Trial name
- MPR_BD (NCT06504485)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 192 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Hepatitis D
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.
- Trial name
- NCT05467553
- Testing
- Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Hepatitis D, Chronic
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy
- Trial name
- NCT05461170
- Testing
- VIR-2218, VIR-3434, NRTI
- Where
- 20 sites in Bulgaria, France and 7 more
- Volunteers
- 95 people
- Sponsor
- Vir Biotechnology, Inc.
Chronic Hepatitis D
Incidence of Viral Hepatitis D Relapses Upon Discontinuation of Bulevirtide in Patients With Chronic Hepatitis D and Negative HDV RNA
This observational study will be conducted in patients with chronic co-infection with hepatitis B and D viruses, with negative PCR for HDV RNA in peripheral blood and no signs of active liver inflammation according to blood…
- Trial name
- NCT06121427
- Where
- Russia
- Volunteers
- 24 people
- Sponsor
- Center of target therapy
Chronic HBV Infection (HBeAg Negative)
REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection
REP 2139-Ca is nucleic acid polymer. Nucleic acid polymers have been previously shown to clear serum hepatitis B virus surface antigen (HBsAg) both preclinically (in duck HBV infected ducks) and in human patients and to act…
- Trial name
- NCT02233075
- Testing
- REP 2139-Ca + Pegasys (TM)
- Where
- Moldova
- Volunteers
- 12 people
- Sponsor
- Replicor Inc.
Chronic Viral Hepatitis B With Delta-Agent
Evaluation of the Effectiveness of the Complex of Carnitine Orotate and Biphenyl Dimethyl Dicarboxylate in the Adjuvant Therapy of Chronic Hepatitis D in Real Clinical Practice: a Prospective Cohort Study
The goal of this observational study is to evaluate the effectiveness of the carnitine-orotate complex and biphenyl dimethyl dicarboxylate in the adjuvant therapy of chronic hepatitis D in real clinical practice: a prospective…
- Trial name
- NCT06068140
- Where
- 7 sites in Kazakhstan
- Sponsor
- Kazakh Association of Internal Medicine Specialists
Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
- Trial name
- NCT07128550
- Testing
- Tobevibart, Elebsiran, Bulevirtide
- Where
- 38 sites in Austria, France and 5 more
- Volunteers
- 150 people
- Sponsor
- Vir Biotechnology, Inc.
Hepatitis D, Chronic, Hepatitis B, Chronic
National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses
This is a multicentre observational study with prospective and retrospective data collection and retrospective data collection and biological collection from patients with HBV/HDV co-infection.
- Trial name
- HEPDELTA (NCT04166266)
- Testing
- Blood draw for the laboratory assessment
- Where
- 38 sites in France
- Volunteers
- 800 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis D
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Multicenter pharmacological observational prospective, no-profit, study. This study was designed to get a "real-life" snapshot across several Italian Hepatology centers.
- Trial name
- D-SHIELD (NCT06122285)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Chronic Hepatitis D Infection
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the…
- Trial name
- NCT05760300
- Testing
- Bulevirtide (BLV)
- Where
- 9 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis Delta With Hepatitis B Carrier State, Chronic Hepatitis b
Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection
The goal of this observational study is to determine the prevalence of hepatitis D virus (HDV) and the distribution of the HDV genotype in patients with chronic hepatitis B infection.
- Trial name
- NCT06638320
- Where
- 3 sites in Vietnam
- Volunteers
- 2,452 people
- Sponsor
- Tam Anh Research Institute
Hepatitis D, Chronic
Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
This study adopts a multicenter, randomized, double-blind, placebo-parallel controlled design to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. A total of 150 subjects are planned to be enrolled.
- Trial name
- NCT07309380
- Testing
- Hepalatide 2.1mg
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Chronic Hepatitis D Infection
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
A phase 2a clinical Study of Hepalatide for Injection in Subjects with Chronic Hepatitis D
- Trial name
- NCT05827146
- Testing
- Hepalatide
- Where
- 3 sites in China, Mongolia
- Volunteers
- 23 people
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Chronic Viral Hepatitis B Without Delta-agent
Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B
The goal of chronic hepatitis B (CHB) treatment is complete and permanent eradication of hepatitis B virus (HBV) from patient's body, which is best represented by serum HBsAg loss accompanied by undetectable serum HBV DNA level.
- Trial name
- TERESA (NCT01595685)
- Testing
- Telbivudine, Entecavir
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Asan Medical Center
Hepatitis D
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Background: Chronic hepatitis D is a liver disease caused by the hepatitis D virus (HDV). It can be severe and progressive. Most people with hepatitis D will develop scarring and damage to the liver.
- Trial name
- NCT02511431
- Testing
- Lonafarnib, Ritonavir
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)